Ligand Pharma (LGND)
NASDAQ:LGND
Want to see LGND full AI Analyst Report?
LGND Stock Chart & Stats
$231.82
-$2.36(-2.14%)
At close: 4:00 PM EST
$231.82
-$2.36(-2.14%)
Day’s Range― - ―
52-Week Range$98.89 - $247.38
Previous CloseN/A
Volume21.09K
Average Volume (3M)247.37K
Market Cap
$4.51B
Enterprise Value$4.76B
Total Cash (Recent Filing)$733.52M
Total Debt (Recent Filing)$451.49M
Price to Earnings (P/E)29.4
Beta1.00
Next Earnings
May 07, 2026EPS Estimate
1.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.02
Shares Outstanding19,941,141
10 Day Avg. Volume257,535
30 Day Avg. Volume247,371
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)3.59
Price to Sales (P/S)13.64
P/FCF Ratio74.76
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue17.76
Enterprise Value/Gross Profit18.20
Enterprise Value/Ebitda24.29
Forecast
1Y Price Target
$268.86Price Target Upside15.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)8.84
Revenue Forecast (FY)$274.49M
Bulls Say, Bears Say
Bulls Say
Balance Sheet And DealmakingA substantial cash balance and deployable capital provide flexibility to pursue accretive partnerships or acquisitions that can expand the royalty portfolio and drive long‑term revenue.
Regulatory ApprovalFDA approval of FILSPARI for a second rare kidney disease expands the drug's indications and increases the U.S. patient opportunity, supporting a larger royalty base for Ligand.
Royalty Revenue ModelLigand's fixed royalty arrangement on partner products means higher FILSPARI uptake converts directly into predictable revenue growth without adding heavy commercial costs.
Bears Say
Contract Revenue TimingContract revenue depends on milestone and payment timing, making near-term top-line results unpredictable and complicating quarterly comparisons.
Product Sales VolatilityCaptisol sales are subject to timing of orders, causing quarter-to-quarter swings that can create volatile reported revenue despite underlying demand.
Revenue VisibilityHeavy variability in contract and product revenue reduces visibility for short-term guidance and places greater emphasis on steady royalty streams for valuation.
Ligand Pharma News
LGND FAQ
What was Ligand Pharma’s price range in the past 12 months?
Ligand Pharma lowest stock price was $98.89 and its highest was $247.38 in the past 12 months.
What is Ligand Pharma’s market cap?
Ligand Pharma’s market cap is $4.51B.
When is Ligand Pharma’s upcoming earnings report date?
Ligand Pharma’s upcoming earnings report date is May 07, 2026 which is in 7 days.
How were Ligand Pharma’s earnings last quarter?
Ligand Pharma released its earnings results on Feb 26, 2026. The company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.497 by $0.523.
Is Ligand Pharma overvalued?
According to Wall Street analysts Ligand Pharma’s price is currently Undervalued.
Does Ligand Pharma pay dividends?
Ligand Pharma pays a Notavailable dividend of $0.456 which represents an annual dividend yield of N/A. See more information on Ligand Pharma dividends here
What is Ligand Pharma’s EPS estimate?
Ligand Pharma’s EPS estimate is 1.82.
How many shares outstanding does Ligand Pharma have?
Ligand Pharma has 19,941,141 shares outstanding.
What happened to Ligand Pharma’s price movement after its last earnings report?
Ligand Pharma reported an EPS of $2.02 in its last earnings report, beating expectations of $1.497. Following the earnings report the stock price went up 2.498%.
Which hedge fund is a major shareholder of Ligand Pharma?
Currently, no hedge funds are holding shares in LGND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ligand Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$268.86 (15.98% Upside)
$268.86 (15.98% Upside)
Blogger Sentiment
Bullish
LGND Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 33.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
120.84%
12-Months-Change
Fundamentals
Return on Equity
13.86%
Trailing 12-Months
Asset Growth
65.71%
Trailing 12-Months
Company Description
Ligand Pharma
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
LGND Company Deck
LGND Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, broad-based financial and operational momentum driven by a rapidly scaling royalty portfolio, sizeable deployable capital and multiple late-stage clinical and commercial catalysts (notably Palvella QTORIN, FILSPARI, Ohtuvayre and CAPVAXIVE). Key 2025 metrics showed high double-digit growth across royalties, revenue and adjusted EPS, and management provided a robust multi-year outlook (23% royalty CAGR to 2030). Headwinds are largely timing and accounting-related: an FDA review extension for FILSPARI FSGS, increased R&D/G&A due to specific investments and some 2025 one-time items that temper 2026 year-over-year comparisons. Overall, the positives materially outweigh the negatives, leaving a constructive outlook.View all LGND earnings summariesLGND Stock 12 Month Forecast
Average Price Target
$268.86
▲(15.98% Upside)
Technical Analysis
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Crinetics Pharmaceuticals
―
Kymera Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
2.67% Insiders
45.63% Mutual Funds
8.63% Other Institutional Investors
17.02% Public Companies and
Individual Investors